Reinstein Eyal, Shoenfeld Yehuda
Department of Internal Medicine B and Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel.
Clin Rev Allergy Immunol. 2007 Apr;32(2):184-7. doi: 10.1007/s12016-007-0003-1.
Thrombosis is a frequent complication of cancer that is a substantial cause of morbidity and mortality. The association of antiphospholipid antibodies (aPL) and cancer has been under investigation for several years. Recent findings suggest an increased prevalence of certain cancers in aPL-positive patients; thus, an intensive search for an occult malignancy is prompted in these patients. In addition, several studies reported on elevated levels of aPL in various malignancies; it seems, however, that aPL levels do not reflect their pathogenicity; therefore, their pathological significance in these subset of patients is still elusive. Continuing research on the association between the antiphospholipid syndrome/aPL and malignancies is important, given the potential impact on the understanding and treatment of both antiphospholipid syndrome and cancer.
血栓形成是癌症常见的并发症,是发病和死亡的重要原因。抗磷脂抗体(aPL)与癌症的关联已被研究多年。最近的研究结果表明,aPL阳性患者中某些癌症的患病率增加;因此,促使对这些患者进行隐匿性恶性肿瘤的密集筛查。此外,多项研究报告了各种恶性肿瘤中aPL水平升高;然而,aPL水平似乎并不反映其致病性;因此,它们在这些患者亚组中的病理意义仍不明确。鉴于抗磷脂综合征/aPL与恶性肿瘤之间的关联研究对理解和治疗抗磷脂综合征及癌症都有潜在影响,持续开展相关研究很重要。